← Back to All US Stocks

CCEL Stock Analysis - CRYO CELL INTERNATIONAL INC AI Rating

CCEL NYSE Services-Misc Health & Allied Services, NEC DE CIK: 0000862692
Recently Updated • Analysis: Mar 22, 2026 • SEC Data: 2025-11-30
AI Rating
STRONG SELL
85% Confidence

📊 CCEL Key Takeaways

Revenue: $31.6M
Net Margin: -7.7%
Free Cash Flow: $5.2M
Current Ratio: 0.59x
Debt/Equity: N/A
EPS: $-0.30
AI Rating: STRONG SELL with 85% confidence

Investment Thesis

Cryo Cell International demonstrates severe financial distress with negative stockholders' equity of -18.6M, indicating the company is technically insolvent. Despite modest positive operating cash flow, the company faces critical liquidity constraints with a current ratio of 0.59x and only 319K in cash against 80.3M in total liabilities. Deteriorating profitability with -7.7% net margins and declining revenue suggests structural business challenges that pose existential risk to the enterprise.

CCEL Strengths

  • + Positive operating cash flow of 5.5M provides near-term runway despite negative net income
  • + Free cash flow margin of 16.6% indicates cash-generative operations when excluding capital investments
  • + Operating income positive at 482.4K shows core business generates some profitability before financing costs

CCEL Risks

  • ! Negative stockholders' equity of -18.6M indicates technical insolvency and severe balance sheet deterioration
  • ! Critical liquidity crisis with current ratio of 0.59x and minimal cash reserves of 319K against substantial liabilities
  • ! Deteriorating earnings with negative net margin of -7.7% and declining revenue; interest coverage ratio of 0.2x indicates inability to service debt from operations
  • ! Liabilities exceed assets by 18.6M, creating existential solvency risk and potential covenant violations

Key Metrics to Watch

CCEL Financial Metrics

Revenue
$31.6M
Net Income
$-2.4M
EPS (Diluted)
$-0.30
Free Cash Flow
$5.2M
Total Assets
$61.7M
Cash Position
$319.0K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

CCEL Profitability Ratios

Gross Margin N/A
Operating Margin 1.5%
Net Margin -7.7%
ROE N/A
ROA -3.9%
FCF Margin 16.6%

CCEL vs Default Sector

How CRYO CELL INTERNATIONAL INC compares to Default sector averages

Net Margin
CCEL -7.7%
vs
Sector Avg 12.0%
CCEL Sector
ROE
CCEL 0.0%
vs
Sector Avg 15.0%
CCEL Sector
Current Ratio
CCEL 0.6x
vs
Sector Avg 1.8x
CCEL Sector
Debt/Equity
CCEL 0.0x
vs
Sector Avg 0.7x
CCEL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

CCEL Balance Sheet & Liquidity

Current Ratio
0.59x
Quick Ratio
0.57x
Debt/Equity
N/A
Debt/Assets
130.1%
Interest Coverage
0.23x
Long-term Debt
$8.4M

CCEL 5-Year Financial Trend

CCEL 5-year financial data: Year 2021: Revenue $31.1M, Net Income $3.6M, EPS $0.45. Year 2022: Revenue $30.3M, Net Income $2.1M, EPS $0.25. Year 2023: Revenue $31.3M, Net Income $2.8M, EPS $0.33. Year 2024: Revenue $32.0M, Net Income -$9.5M, EPS $-1.14. Year 2025: Revenue $32.0M, Net Income $402.1K, EPS $0.05.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CRYO CELL INTERNATIONAL INC's revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $0.05 reflects profitable operations.

CCEL Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
16.6%
Free cash flow / Revenue

CCEL Quarterly Performance

Quarterly financial performance data for CRYO CELL INTERNATIONAL INC including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $7.8M $749.4K $0.09
Q2 2025 $7.9M $355.8K $0.04
Q1 2025 $7.9M $282.9K $0.03
Q3 2024 $7.9M $680.6K $0.08
Q2 2024 $7.8M $221.0K $0.03
Q1 2024 $7.8M $556.2K $0.07
Q3 2023 $7.7M $466.8K $0.06
Q2 2023 $7.6M $221.0K $0.03

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CCEL Capital Allocation

Operating Cash Flow
$5.5M
Cash generated from operations
Stock Buybacks
$169.5K
Shares repurchased (TTM)
Capital Expenditures
$230.5K
Investment in assets
Dividends Paid
$3.2M
Returned to shareholders

CCEL SEC Filings

Access official SEC EDGAR filings for CRYO CELL INTERNATIONAL INC (CIK: 0000862692)

📋 Recent SEC Filings

Date Form Document Action
Mar 12, 2026 8-K ccel-20260309.htm View →
Feb 27, 2026 10-K ccel-20251130.htm View →
Jan 9, 2026 4 xslF345X05/ownership.xml View →
Jan 9, 2026 4 xslF345X05/ownership.xml View →
Jan 9, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about CCEL

What is the AI rating for CCEL?

CRYO CELL INTERNATIONAL INC (CCEL) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are CCEL's key strengths?

Positive operating cash flow of 5.5M provides near-term runway despite negative net income. Free cash flow margin of 16.6% indicates cash-generative operations when excluding capital investments.

What are the risks of investing in CCEL?

Negative stockholders' equity of -18.6M indicates technical insolvency and severe balance sheet deterioration. Critical liquidity crisis with current ratio of 0.59x and minimal cash reserves of 319K against substantial liabilities.

What is CCEL's revenue and growth?

CRYO CELL INTERNATIONAL INC reported revenue of $31.6M.

Does CCEL pay dividends?

CRYO CELL INTERNATIONAL INC pays dividends, with $3.2M distributed to shareholders in the trailing twelve months.

Where can I find CCEL SEC filings?

Official SEC filings for CRYO CELL INTERNATIONAL INC (CIK: 0000862692) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CCEL's EPS?

CRYO CELL INTERNATIONAL INC has a diluted EPS of $-0.30.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 22, 2026 | Data as of: 2025-11-30 | Powered by Claude AI